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Interventions to reduce anticholinergic burden in adults aged 65 and over: 1 
A systematic review 2 
ABSTRACT 3 
Introduction:  Older age is associated with multi-morbidity and polypharmacy with high 4 
anticholinergic burden (ACB). High ACB is linked to adverse events such as poor physical 5 
functioning, dementia, cardiovascular disease and falls. Interventions are needed to reduce 6 
this burden.  7 
Aims/Objectives:  The aim was to systematically review the literature to identify and describe 8 
studies of clinical and cost effectiveness of interventions designed to reduce ACB in 9 
adults(≥65years), on polypharmacy regimes, compared with usual care. The objective was to 10 
answer the questions: What are the contents of the interventions? Were these interventions 11 
clinically effective? Were these interventions cost effective? 12 
Design, Setting and Participants: Systematic review of interventions to reduce anticholinergic 13 
burden in adults aged 65 and over in any clinical setting 14 
Methods: Eligible papers reported primary or secondary research describing any type of 15 
intervention including systematic reviews, Randomised Controlled Trials (RCTs), Controlled 16 
Clinical trials or pre/post non-randomised intervention studies (PPIs) published in English 17 
from January 2010 to February 2019. Databases searched included CINAHL, Ovid MEDLINE, 18 
EMBASE and The Cochrane Central Register of Controlled Trials (CENTRAL).  19 
Results: The search yielded 5862 records. Eight studies (4 RCTs, 4PPIs) conducted in hospital 20 
(4), community (2), nursing homes (1), and retirement villages (1) met the inclusion criteria. 21 
Pharmacists, either individually or as part of a team, provided the intervention in the majority 22 
of studies (6/8). Most (7/8) involved individual patient medication review followed by 23 
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feedback to the prescriber. Two of the four RCTs and all non-RCTs reported a decrease in ACB 24 
following the intervention. No study reported cost outcome. 25 
Conclusions and Implications: Pharmacists may be well placed to implement an ACB reduction 26 
intervention. This is the first systematic review of interventions to reduce ACB in older adults 27 
and highlights the need for development and testing of high quality pragmatic clinical and 28 
cost-effectiveness trials in community and specific patient populations at high risk of harm 29 
from ACB.    30 
 [PROSPERO registration: CRD42018089764]   31 
 32 
Word count: 299 words 33 
 34 
  35 
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Introduction  36 
Anticholinergic drugs act by blocking parasympathetic nerve impulses 1 and, hence, control 37 
involuntary muscle movement 2. They are, therefore, commonly prescribed to treat 38 
gastrointestinal disorders (e.g. diarrhoea, ulcers, spasms), overactive bladder (e.g. 39 
incontinence) and to relieve symptoms of Parkinsonism. In addition, antidepressants and 40 
antipsychotics which are often used among older people also have anticholinergic properties. 41 
The prevalence of their use is steadily increasing (estimates vary from 37-63%) 3-5, particularly 42 
in the ageing population. However, anticholinergics are associated with a wide range of 43 
adverse effects, and there have been numerous calls for interventions to reduce the use of 44 
such drugs. The challenge is to minimise the adverse effects of anticholinergic drugs whist 45 
still retaining the benefits.  46 
The term “anticholinergic burden” refers to the cumulative anticholinergic action resulting 47 
from concomitant use of multiple medications with anticholinergic properties 1. It is 48 
recognised that high anticholinergic burden is linked to adverse events such as poor physical 49 
functioning, dementia, and falls 6, 7. However, to date there are few studies which examine 50 
the clinical and cost effectiveness of using these tools in practice to change prescribing.    51 
Therefore, the aim of this study was to systematically review the literature to identify and 52 
describe studies of the clinical and cost effectiveness of interventions designed to reduce the 53 
anticholinergic burden in adults aged 65 and over compared with usual care, and assessed 54 
with any outcome measure. The specific research questions were: What are the contents, or 55 
ingredients, of the interventions? Were the interventions clinically effective? Were the 56 
interventions cost effective? 57 
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Methods 58 
The systematic review protocol was registered in PROSPERO (CRD42018089764). The 59 
literature search was systematically conducted in accordance with the general principles of 60 
the Centre for Reviews and Dissemination (CRD) guidance for undertaking reviews in 61 
healthcare 8 and the Cochrane Handbook for Systematic Reviews of Interventions 9, and is 62 
reported in accordance with the PRISMA statement 10. The studies and interventions are 63 
described according to the TIDieR, CONSORT or STROBE checklists 11-13, as appropriate. 64 
Search strategy, inclusion and exclusion criteria  65 
This review included primary or secondary research studies that reported a relevant 66 
intervention or interventions, including  systematic reviews, randomised controlled trials 67 
(RCTs), controlled clinical trials (CCTs), pre-post intervention non randomised studies (PPIs), 68 
either delivered by a single health care professional or by multidisciplinary team, published 69 
from January 2010 to February 2019 in English language. We restricted the time period of 70 
studies to 2010 onwards to provide a realistic picture of contemporary practice and 71 
populations as well as based on our knowledge that most studies which have demonstrated 72 
adverse effects of ACB have been published from early 2000s with some intervention studies 73 
from 2010. Epidemiological studies, case reports, reports published in non-English language 74 
for which a translation could not be organised and animal studies were excluded. The 75 
participants eligible for inclusion were adults aged 65 and over on long term medication, 76 
which was defined as using medications for more than 12 weeks, for the purposes of this 77 
study. Eligible interventions were any interventions/strategies that aimed to reduce 78 
anticholinergic burden. The comparator was usual care in the respective setting. The 79 
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outcome measures were 1) medication use, including number of drugs and anticholinergic 80 
burden or other score, 2) patient outcomes such as falls etc., and 3) costs outcomes. 81 
Methods for identification of studies 82 
Databases including CINAHL, Ovid MEDLINE, EMBASE and The Cochrane Central Register of 83 
Controlled Trials [CENTRAL]) were searched for original articles and conference abstracts, and 84 
the grey literature was identified in Google Scholar from 2010 to March 2018. This was 85 
updated in February 2019. The search terms used were: anticholinergic$.tw. OR cholinergic 86 
antagonist$.tw. OR antimuscarinic$.tw. OR muscarinic antagonist$.tw. AND Anticholinergic 87 
Syndrome OR Drug-Related Side Effects OR adverse effect$.tw. OR adverse adj2 effect$.tw. 88 
OR adverse reaction$.tw. OR adverse adj2 reaction$.tw. OR side effect$.tw. OR burden.tw 89 
AND limit to (human and year= “2010-Current” and “all aged (65 and over)”). The search 90 
strategy was developed for Ovid MEDLINE and was adapted for use in the other databases 91 
(CINAHL, EMBASE and CENTRAL).  92 
Data collection and analysis 93 
Two reviewers (AN, together with one of PKM, CMB or MC) independently screened titles 94 
and abstracts of records to determine whether they potentially met the inclusion criteria. 95 
Next, full-texts of potentially eligible studies were further examined by two reviewers (AN, 96 
together with one of PKM, CMB or MC) against the inclusion criteria to determine eligibility. 97 
Discrepancies were resolved by discussion between reviewers. 98 
A data extraction form was developed for the purposes of this review; one reviewer (AN) 99 
extracted data from all eligible studies and one reviewer (MC) cross-checked the data. Items 100 
from standard reporting checklists were included in the form; they were the TIDieR checklist 101 
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11 to describe the interventions, the CONSORT 2010 checklist 12 to describe the RCTs and the 102 
STROBE checklist 13 for observational (non-randomised) studies, respectively. Disagreements 103 
were resolved by discussion between a minimum of two reviewers. 104 
Quality assessment 105 
Two reviewers (AN and MC) independently assessed risk of bias of included studies. The RCTs 106 
were assessed by the Cochrane Collaboration tool for assessing risk of bias 9. Non 107 
randomised studies were assessed using the Critical Appraisal notes and checklists from the 108 
Scottish Intercollegiate Guidelines Network (SIGN), UK 14. 109 
Strategy for data synthesis 110 
Information extracted was tabulated and described narratively. The original intention was to 111 
quantify the evidence by meta-analysis, but this was not possible due to heterogeneity of the 112 
included studies.  113 
Results 114 
Description of included studies 115 
The search strategy yielded 5862 records. After removing 325 duplicates, 5543 titles and 116 
abstracts were screened; of these, full text articles were retrieved for 33 potentially eligible 117 
papers from which eight  (seven full text papers15-17, 19-22 and one conference abstract 18 met 118 
the eligibility criteria and were included in the review. Details of the study selection process 119 
are shown in Figure 1. 120 
 121 
 122 
 123 
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Study characteristics 124 
The eight included studies  (4 Randomised Controlled Trials (RCTs) 15-18 and 4 (Non-125 
randomised Pre-Post Intervention studies) (PPIs) 19-22) were from Australia 15, 19, Norway 16, 126 
Spain 21, the Netherlands 18, United States 17, 20 and United Kingdom 22. One RCT was a pilot 127 
study using an unblinded cluster randomized design 15. No systematic reviews were 128 
identified. Pharmacists, either individually or as part of a team, provided the intervention in 129 
the majority of studies (six of eight studies) 16-21. A summary of the characteristics of the eight 130 
included studies is presented in Table 1. Participants were predominantly Caucasian and 131 
female.  The intervention duration of the studies varied from median 6.5 days 21 to 3 months 132 
15, 18. The audit and feedback study 22 was conducted in two phases; first, in April/May 2011 133 
and, second, in June 2011. There was one multi-centre RCT 15, and the remainder were single 134 
centre studies 16-22. 135 
Studies were conducted in various settings including hospital 17, 20-22, the community 18, 19, 136 
nursing homes 16 and self-care retirement village 15. The majority of studies had small sample 137 
sizes (n=50-115 participants) with the exception of one community-based PPI that included 138 
372 participants19. The mean age of participants in all eight studies was over 75 years. Study 139 
design and participant characteristics for each included study are presented in Appendix 1. 140 
None of the studies mentioned the involvement of patients and/or other stakeholders (e.g. 141 
health professionals, policy makers) with regards to study/intervention design. 142 
Risk of bias assessment 143 
None of the four RCTs complied fully with the Cochrane Collaboration tool for risk of bias 144 
assessment, and one study met only one criterion 15. Blinding of participants and outcomes 145 
had the lowest compliance. Sequence generation was judged to be adequate in only one 146 
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study 17, whilst the remaining three studies did not report sufficient detail to enable an 147 
assessment. The conference abstract 18 included little methodological detail resulting in a 148 
high proportion of ‘unclear’ judgements. The risk of bias assessments of the RCTs are 149 
displayed in Figure 2. 150 
Assessment of the risk of bias for the four PPI studies demonstrated that they addressed 151 
appropriate and clearly focused research questions, had reliable methods of assessment of 152 
exposure, and valid and reliable outcome measures. However, the criterion of selection bias 153 
was not applicable given that there was no control arm in the four PPI studies 19-22. The 154 
summary of the critical appraisal notes and SIGN checklists for individual PPIs is provided in 155 
Appendix 2.  156 
Contents of the interventions 157 
The summary of interventions in the included studies is presented in Appendix 3 and 158 
reported according to the TIDieR checklist. The intervention provider(s) in six of the eight 159 
included studies was a pharmacist, either individually or as part of a team undertaking 160 
patient medication review followed by feedback to the prescriber 16-21; in another study a 161 
clinical pharmacologist and geriatrician made recommendations for prescribing to a GP 15; 162 
and the final study used an  audit and feedback intervention delivered by consultants in 163 
geriatric medicine 22.   164 
The interventions that included recommendations to the prescriber adopted a range of 165 
different approaches, for example, in one hospital study conducted in Spain, pharmacists 166 
conducted clinical interviews, followed by medicine reconciliation and checking of medicine 167 
appropriateness against the STOPP/START criteria before providing recommendations to the 168 
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prescriber 21.  In other studies, a clinical pharmacist performed a note based medication 169 
review and then provided verbal recommendations to respective physicians in nursing homes 170 
(Norway) 16, community settings (the Netherlands) 18, or in an Alzheimer’s Disease Centre 171 
(United States) 17. In another US study, a pharmacist undertook a patient medication review 172 
using the hospital Electronic Health Record (EHR) to review patients’ medication and then 173 
provided electronic recommendations to the prescribers 20. In self-care retirement villages 174 
(Australia), recommendations were made by a geriatrician and clinical pharmacologist 15. The 175 
pre-post intervention clinical audit study in the UK 22 involved feedback to the clinicians by 176 
posting a list of drugs with respective anticholinergic burden in the second phase of audit on 177 
the ward drug trolley to inform the geriatrician who looked after the patient. 178 
Outcomes of interventions 179 
A summary of results of clinical effectiveness of individual studies is presented in Table 2. A 180 
meta-analysis was not possible due to heterogeneity of the studies with regard to study 181 
designs (e.g. use of different measures of anticholinergic burden) and outcome measures. 182 
Almost all the studies chose to focus on measures of anticholinergic use as their main 183 
outcome 15, 17, 20-22. 184 
RCTs 185 
Two of the four RCTs reported that anticholinergic burden decreased significantly following 186 
the intervention 16-17. The trial carried out in the nursing home setting resulted in a 187 
statistically significant reduction in the median Anticholinergic Drug Scale (ADS) from baseline 188 
for the intervention group and remained unchanged in the control group (p<0.0001) 16. The 189 
trial in the Alzheimer’s Disease Centre showed a statistically significant improvement in the 190 
Medication Appropriateness Index (MAI) (p=0.04) and reduced ADS score (p=0.03) in the 191 
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intervention group compared with the control group 17. However, the changes in DBI 192 
following the intervention in the cluster RCT conducted in the Australian retirement villages 193 
were not significantly different between the intervention and control group 15. Furthermore, 194 
the RCT that involved a medication review by a pharmacist in the community (n= 157, with 195 
4.3% attrition rate over 3 months duration) showed no difference between the groups in the 196 
proportion of patients having a decrease in DBI ≥0.5 (14.7% vs. 15.9%; OR=0.91, 95%CI=0.38-197 
2.18), although there was a reduction in sedative side effect 18.   198 
Non-randomised PPI studies 199 
All four pre-post intervention studies (PPIs) showed significant reductions in anticholinergic 200 
burden following the intervention 19-22. In the study in Australia conducted in the community, 201 
the total DBI was significantly reduced (p<0.001) and pharmacists’ recommendations were 202 
associated with a decrease in the use of Potential Inappropriate Medications (PIMs) 19. In the 203 
Electronic Health Record (EHR) medication review study, the acceptance rate of pharmacists’ 204 
recommendations by primary care physicians was 50% (95%CI:37-63%) and the 205 
Anticholinergic Risk Scale (ARS) score was reduced significantly (p=0.0003) after intervention 206 
20. In the STOPP/START study, both the ADS and ARS scores decreased significantly (p=0.001 207 
and p=0.047 respectively) between admission and discharge 21. Finally, in the feedback audit 208 
and feedback study, the ARS scores were significantly decreased and there was a higher 209 
proportion of patients on anticholinergics who had their medications either stopped or 210 
reduced (OR=5.0, 95%CI:1.4-17.8) compared to pre-intervention 22.  211 
Clinical and Cost effectiveness of interventions 212 
One RCT reported no significant differences in the results of cognitive function tests between 213 
groups, despite a significant decrease in anticholinergic use following the intervention 16. 214 
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None of the included studies reported information on the cost-effectiveness of the 215 
interventions. 216 
Discussion  217 
This is believed to be the first systematic review assessing information about interventions 218 
that reduce anticholinergic burden in adults aged 65 and over.  This work identified eight 219 
studies reporting interventions to reduce anticholinergic burden in patients aged 65 and 220 
over. The interventions were primarily provided by pharmacists using patient-centred 221 
approaches, but there was no consistency in the specific approach used. Systematic reviews 222 
of general deprescribing in older people have also reported the delivery of deprescribing 223 
interventions by pharmacists, albeit in a smaller number of included studies (4/9 and 2/18 224 
studies included in the respective reviews) 23, 24.  225 
Two of the four identified RCTs 16-17 and all four PPIs 19-22 demonstrated that the intervention 226 
reduced anticholinergic burden effectively. These findings are in line with two systematic 227 
reviews (including randomised and non-randomised studies) of general deprescribing in 228 
people aged 65 and over, which reported that deprescribing reduced medication use 24, 25. 229 
The two RCTs that reduced anticholinergic burden were both small trials of short duration 16, 230 
17. The RCT conducted in the Alzheimer’s Disease Centre was the only study to report a 231 
clinical outcome (i.e. cognitive function; the Consortium to Establish a Registry for 232 
Alzheimer’s Disease 10-wordlist test for immediate recall) but showed no statistical 233 
differences between the intervention and control group 16. Loss to follow-up rate in three of 234 
the four RCTs was low 15, 17, 18 ,suggesting that the interventions were acceptable and 235 
feasible, in line with the findings of a systematic review of general deprescribing in older 236 
adults 24. 237 
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However, no studies in the review reported costs or cost-effectiveness and the majority of 238 
the studies did not include an objective clinical outcome such as physical function, 239 
cardiovascular diseases, falls and mortality. Recent systematic reviews have found the 240 
evidence on the impact of general deprescribing on clinical outcomes to be ambiguous 23-25. 241 
Therefore, it appears that the current evidence base on the impact of deprescribing in older 242 
adults is inconclusive. 243 
Strengths of the review included a comprehensive search of all potentially relevant articles 244 
and the use of explicit, reproducible criteria in the selection of articles included. The search 245 
was limited to 2010 onwards, providing contemporary practice relevant to the current ageing 246 
population with multi-morbidity and polypharmacy as well as the growing number of ACB 247 
medications in the literature. The search strategy was conducted on more than one database 248 
and a minimum of two researchers screened abstracts and full texts independently to select 249 
eligible publications. Furthermore, the review was conducted rigorously according to 250 
published guidelines 9. Whilst emphasizing the need for   RCT evidence - the ‘gold standard’ 251 
for health research- this review has also summarised evidence from other types of studies.  252 
However, overall the studies included had many limitations. Sample sizes were small, and two 253 
self-identified as pilot studies. Most had considerable methodological limitations introducing 254 
bias, and there were only four randomised controlled trials. In the RCTs, it was not possible to 255 
blind participants or personnel due to the nature of the interventions. The inclusion of non-256 
randomised PPIs in the review increased the available body of evidence but the limitations of 257 
this study design should be borne in mind and their findings interpreted with caution. In 258 
addition, interpretation of PPI studies is not straight forward. Changes in the outcome of 259 
interest may be due to the intervention; however, it may also reflect disease natural history 260 
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(as the condition improves over time or clinical therapy improves with experience), patient 261 
selection (patients before and after the intervention may have differed in clinically important 262 
attributes), or placebo effects (because neither patient nor provider is blinded). In addition, 263 
there is a natural tendency for processes to regress to the mean, which may occur without 264 
intervention. 265 
Across studies, the outcomes that were measured were not similar enough to be statistically 266 
combined, for example, Anticholinergic Drug Scale (ADS), Anticholinergic Risk Scale (ARS), 267 
Anticholinergic Cognitive Burden (ACB) scale, Drug Burden Index (DBI) changes, Medication 268 
Appropriate Index (MAI) changes, recommendation acceptance rate, perceived health status 269 
and also Consortium to Establish a Registry for Alzheimer’s disease 10-wordlist test. None of 270 
the included studies tested long-term effectiveness of the intervention, with the longest 271 
study duration being 3 months. All studies were conducted in different countries and 272 
therefore generalisability across countries is uncertain due to differences in infrastructure 273 
and also background (e.g. lifestyle and ethnicity) of participants. 274 
Only one study examined a clinical outcome. In that study, participants’ cognitive function did 275 
not change despite the median ADS score decreasing by 2 units in the intervention group 16. 276 
However, a previous study suggested that performance of individuals with higher 277 
anticholinergic burden in cognitive tasks was poorer than that of those with lower ACB 26. 278 
This may be due to the fact that detection of the impact of reducing ACB on cognition could 279 
require a longer follow-up. A study with 8 week of follow up was not of sufficient length to 280 
assess the long-term impact of the intervention 17. One study did not include short-term 281 
medications when calculating anticholinergic burden, and that might have influenced the 282 
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outcome measurement in ACB scores or scales 21. Current knowledge gaps identified in this 283 
review and recommendations for future research are presented in Table 3. 284 
 285 
Conclusions and Implications 286 
This systematic review suggests that pharmacists may be well placed to provide an 287 
anticholinergic reduction intervention. Further rigorous research is needed to confirm this 288 
finding, identify the best approach, its cost effectiveness and longer term patient outcomes 289 
in community settings as well as for specific patient populations.  290 
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Table 1 Summary of study characteristics of the eight included studies 
Study ID  Inclusion and exclusion criteria (participants) Length of 
follow-up 
Baseline 
anticholinergic 
drug scores 
Baseline information Outcomes reported 
RCTs 
Gnjidic 
2010 15 
Inclusion criteria: Residents were included if 
they were aged ≥ 70 years and if they 
consulted their GPs regularly. 
Exclusion criteria: NR 
 
3 months NR Exposed to anticholinergic 
drugs Intervention group = 8 
(14.0%), Control group =19 
(32.8%); mean DBI score 
Intervention group = = 0.22 
+/- 0.42 , Control group =  
0.26 +/- 0.34 
Primary: change in DBI at 3 months 
after intervention as compared to 
baseline. 
Kersten 
2013 16 
Inclusion criteria:  Patients who have  
anticholinergic drug scale (ADS) of greater than 
or equal 3 (by Channahan et. al., 2006)  
Exclusion criteria:  Patients with blindness, 
deafness, aphasia, delirium, or severe 
dementia (score 3 on the 
Clinical Dementia Rating scale) 
8 weeks ADS median 
Intervention 
group = 4 
(IQR=3-5), 
Control group 
4(IQR=3-5) 
Overall median 
ADS score 4 
Baseline Mini-Mental State 
Examination score 
Intervention group = 20.5 
(16-25), Control group = 20 
(16-22); Whole mouth 
resting salivary flow (g/min) 
Intervention group = 0.21 
(0.07-0.54), Control group = 
0.22 (0.16-0.37); SAA 
(pmol/mL atropine 
equivalents) Intervention 
group = 4.27 (2.43-7.96), 
Control group = 4.79 (2.68-
8.71) 
Primary: Consortium to Establish a 
Registry for Alzheimer’s Disease 10-
wordlist test for immediate recall. 
Secondary: Mini-Mental Sate 
Examination for delayed recall and 
recognition of words, Dry mouth (saliva 
flow at 4 week follow-up), and serum 
anticholinergic activity (SAA) at 4 and 8 
weeks following intervention. 
Consortium to Establish a Registry for 
AD 10-wordlist for delayed recall and 
recognition 
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Study ID  Inclusion and exclusion criteria (participants) Length of 
follow-up 
Baseline 
anticholinergic 
drug scores 
Baseline information Outcomes reported 
Moga 
2017 17 
Inclusion criteria: Patients who were actively 
enrolled in the ADC cohort; 65 years of age and 
older; reporting at least one drug with 
anticholinergic properties at their annual ADC 
visit; and willing to participate in our 
intervention study. 
Exclusion criteria: Patient who were moderate 
or severe dementia as measured by a Clinical 
Dementia Rating (CDR)  global score ≥ 2, or 
lived in a long-term care facility at the time of 
enrolment 
8 weeks ADS median 
Intervention 
group = 2.8 +/-
1.9, Control 
group 2.9 +/-
1.3 
Medication appropriateness 
index Intervention group 
mean ;12.2 +/- 7.9 , Control 
group 13.0 +/- 4.4   ; 
Intervention group; number 
of anticholinergic drugs 1, ≥2 
= 14 (56.0%), 11(44.0%), 
respectively, number of 
anticholinergic drugs 1, ≥2 = 
11 (44.0%), 14(56.0%),  
respectively 
Co-primary: the impact of the targeted 
MTM intervention on potentially 
inappropriate anticholinergic use by 
evaluating change from baseline to end 
of study in: appropriateness of 
anticholinergic medication prescribing, 
as measured by the medication 
appropriateness index (MAI); and 
anticholinergic burden as measured by 
the number of anticholinergic drugs 
used and the anticholinergic drug scale 
(ADS)                  
Secondary: the change in perceived 
health status from baseline to the end-
of-study visit as measured using the SF-
36, a validated instrument that 
evaluates eight health domains 
categorized into three major health 
attributes. 
van der 
Meer 
2016  18 
Inclusion criteria: Community-dwelling patients 
aged ≥ 65 years, using ≥ 5 medications for ≥ 3 
months including at least one medication with 
an ATC code from the groups N05 or N06 and 
having a DBI ≥ 1 were included in the study 
Exclusion criteria: NR 
3 months NR Mean DBI 2.6 Primary outcome:  the difference in 
proportion of patients having a 
decrease of DBI ≥ 0.5 between the 
intervention and control arm at 3 
month follow-up                      
Secondary: anticholinergic and sedative 
effects, falls, cognitive function, 
activities of daily living, quality of life, 
hospital admission and mortality     
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Study ID  Inclusion and exclusion criteria (participants) Length of 
follow-up 
Baseline 
anticholinergic 
drug scores 
Baseline information Outcomes reported 
Non-randomised PPI studies 
Castelino 
2010 19 
Inclusion criteria: Patients (aged ≥65 years). 
Patients were referred to the HMR service on 
the basis of standard criteria, e.g. taking ≥ 5 
regular medications; taking ≥ 12 doses of 
medication/day; significant changes made to 
the medication regimen in the last 3 months; 
taking a medication with a narrow therapeutic 
index; and recent (within the last 4 weeks) 
discharge from a facility/hospital. 
Exclusion criteria: NR 
NR NR Drug Burden Index 
medications prescribed 
(no.[mean(SD)] = 390 
[1.05(1.1)], Anticholinergic 
medication prescribed 
(no.[mean(SD)] = 110 
[0.29(0.5)]; Potentially 
Inappropriate Medications 
(PIMs) prescribed (no.) = 
196, PIMs independent of 
diagnosis [no.(SD)] = 170 
(86.7), PIMs dependent of 
diagnosis [no.(SD)] = 26 
(13.3)    
Primary: the total DBI score at baseline 
and post-HMR. The data were also 
examined to determine the extent of 
PIM use (2003 Beers’ criteria), and the 
number and nature of pharmacists’ 
recommendations 
Hanus 
2016 20 
Inclusion criteria: The medical records of 
patients 
who met the following criteria were evaluated 
bimonthly: 1) Primary Care Physician (PCP) visit 
within 2 weeks; (2) three or more inpatient 
hospitalizations or emergency department 
visits in the past year; and (3) ten or more 
active medications. 
Exclusion criteria: NR 
NR average ARS = 
5.2 +/- 2.5 
NR Primary: ARS score was calculated for all 
eligible patients. Patients with an ARS 
score of 3 or more underwent 
comprehensive medical record review 
to establish clinically relevant 
medication therapy recommendations. 
These recommendations were made to 
patients' PCPs via the shared EHR 
before the patient's upcoming visit, with 
enough time for the PCP to evaluate 
and implement them. Finally, post-visit 
recommendation outcomes were 
determined by the pharmacist and 
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Study ID  Inclusion and exclusion criteria (participants) Length of 
follow-up 
Baseline 
anticholinergic 
drug scores 
Baseline information Outcomes reported 
categorized as “accepted” if 
implemented or “rejected” if ignored. 
Rojo-
Sanchıs 
2017 21 
Inclusion criteria: Patients more than 80 years 
old who were admitted to the acute geriatric 
unit of tertiary hospital 
Exclusion criteria: Patients who were 
readmission in less than 3 months, receiving 
palliative care before or during admission, and 
death within the hospitalization period 
Median 
length of 
stay was 
6.5 days 
ACB = 1.9 
(95%CI=1.6-
2.2), ADS = 1.4 
(95%CI=1.2-
1.8), ARS =0.9 
(95%CI=0.7-
1.2) 
At admission, 71.6%, 50.7%, 
and 79.1% of the study 
patients were treated with 
an anticholinergic drug listed 
on the ADS, ARS, and ACB 
scales, respectively. The 
most commonly used 
anticholinergic drugs at 
admission were furosemide 
(61.2% of patients; when 
considering ADS and ACB 
scales) and trazodone 
(28.4% of patients; when 
considering ARS scale). 
Primary: anticholinergic burden was 
calculated according to the score 
assigned to each drug on the ADS, ARS, 
and ACB scales. Thus, the 
anticholinergic burden of each patient 
on admission and at discharge was 
determined using each of the three 
scales 
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Study ID  Inclusion and exclusion criteria (participants) Length of 
follow-up 
Baseline 
anticholinergic 
drug scores 
Baseline information Outcomes reported 
Tay 2014 
22 
Inclusion criteria: Patients age at least 65 years 
who admitted to the word 
Exclusion criteria: NR 
First 
phase: 
25th April 
2011 to 
9th May; 
second 
phase: 5th 
June 2011 
to 20th 
June 2011 
  
Median ARS 
(IQR); First 
phase 
preadmission = 
0(0-1) First 
phase Post 
review = 0(0-1) 
p=0.01, Second 
phase 
preadmission = 
0(0-1) First 
phase Post 
review = 0(0-0) 
p=0.002 
On anticholinergics 
First phase = 33%, Second 
phase = 31% 
Primary: Anticholinergic drug exposure 
[number of anticholinergic drugs and 
Anticholinergic Risk Scale (ARS) score] 
Note ACB = Anticholinergic Cognitive Burden Scale, ADS = Anticholinergic Drug Scale, ARS = Anticholinergic Risk Scale, CI= Confidence Interval,                       DBI 
= Drug Burden Index, HMR = Home Medication Review, IQR = Interquartile range, NR = Not reported, PIMs = Potential Inappropriate Medication
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Table 2 Summary of results of cost-effectiveness of the eight included studies  
Study ID  Summary of results reported by the eight included studies 
RCTs 
Gnjidic 2010 15 In this cluster randomized trial, there was a significant imbalance at baseline where 19 of 57 (33.3%) participants in the intervention group 
and 31 of 58 (53.4%) participants in the control group had a DBI >0. Following the intervention, DBI decreased in 6 of 19 (32%) in the 
intervention group, and 6 of 31 (19%) in the control group (p=0.13). DBI increased in 4 participants in the intervention group (two in each 
group, DBI=0 and DBI >0, respectively) and none in the control group. 
 
GPs identified the following barriers to reducing anticholinergic and sedative drugs: uncomfortable altering prescriptions initiated by 
specialists; unable to influence patients' altitudes; unaware of patients' medications and strong clinical indication. 
Kersten 2013 16 After 8 weeks, the median ADS score was significantly reduced from 4 to 2 in the intervention group, whereas it remained unchanged in the 
control group (p <0.0001). The significant reduction in ADS score was achieved by replacement or withdrawal of anticholinergic drugs. No 
statistically significant difference between the means was detected in any of the cognitive tests after 8 weeks (p > 0.19).  The saliva flow or 
SAA did not differ significantly between the subgroups at the follow-ups, that is, at 4 weeks (p = 0.34) and 8 weeks (p = 0.83), respectively.  
Moga 2017 17 The number of anticholinergic drugs was reduced significantly in the intervention group. The intervention group was over 5 times as likely 
as the control group to discontinue an inappropriate anticholinergic medication. The targeted MTM intervention resulted in statistically 
significant CDR adjusted differences between groups with regard to improved MAI (change score of 3.6 (±1.1) for the MTM group as 
compared with 1.0 (±0.9) for the control group, p = 0.04) and ADS (change score of 1.0 (±0.3) for the MTM group as compared with 0.2 
(±0.3) for the control group, p = 0.03). 
van der Meer 2016 
18 
Multilevel analysis showed no significant difference in the proportion of participants having a decrease in DBI ≥ 0.5 between intervention- 
and control arm (14.7% versus 15.9%, OR=0.91, 95% CI 0.38-2.18], p=0.836). Patients in the intervention group reported fewer sedative 
effects (p=0.002).  The intervention was not effective in reducing the DBI in this frail group of older people. 
Non-randomised PPI studies 
Castelino 2010 19 Overall, medications contributing to the DBI (i.e. medications with sedative or anticholinergic properties) and PIMs were identified in 60.5% 
(n = 225) and 39.8% (n = 148) of the patients, respectively. Following pharmacist recommendations during the HMR service, medications 
contributing to the DBI were identified in 51.6% (n = 192) of the patients. A statistically significant reduction in the sum total of DBI scores 
for all patients was observed following pharmacists’ recommendations during the HMR service (206.9 VS 157.3, p < 0.001). Pharmacists’ 
recommendations also led to a decrease in the use of PIMs, which were identified in 28.2% (n = 105) of the patients following the HMR 
service. 
Hanus 2016 20 The aggregate post-intervention mean ARS score was 3.8±3.3, resulting in a mean change of 1.3±2.6 (p=0.0003). 89 medication therapy 
recommendations made to 21 PCPs. An overall recommendation acceptance rate of 50% (95%CI= 37%-63%) was observed.  
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Rojo-Sanchıs 2017 21 There was a significant reduction in anticholinergic burden between admission and discharge according to the ARS (P = 0.001) and ACB (P = 
0.047) scales, and a non-significant reduction in anticholinergic burden according to the ADS scale (P = 0.087). The anticholinergic burden 
was reduced in 32.8%, 34.3%, and 37.3% of the patients according to the ARS, ACB and ADS scales, respectively. 
Tay 2014 22 Fifty-three anticholinergic drugs were prescribed at baseline (preadmission) to 45/140 (32%) patients included throughout both phases of 
the audit. ARS scores fell significantly in both arms of the audit, more so in the second arm. The proportion of patients on anticholinergics 
who had their medications either stopped or reduced rose significantly from 8 out of 23 (35%) in the first arm to 16 out of 22 (72%) in the 
second arm (OR 5.0, 95% CI 1.4–17.8). The total number of anticholinergic drugs prescribed fell from 29 to 20 in the first phase, and from 
24 to 11 in the second.  
Note CDR= Clinical Dementia Rating, DBI = Drug Burden Index, HMR = Home Medication Review, NR = Not reported, PIMs = Potential Inappropriate Medications
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Table 3 Current knowledge gaps identified in this review and recommendations for future studies 
Current knowledge gaps Recommendations for future studies 
No RCTs reported the involvement of stakeholders during 
intervention design and/or process evaluation of the interventions. 
 
 
 
No studies in the review reported costs or cost-effectiveness.  
 
 
 
No long-term follow-up of clinical outcome(s) which are 
associated with ACB reduction intervention are available. 
 
Patients and other stakeholders should be involved from the 
design stage to evaluation and implementation of any future 
interventions. 
 
 
We recommend the assessment of costs or cost-effectiveness 
in future studies. 
 
 
Longer-term follow up of clinical outcomes, such as cognitive 
function, is recommended. 
 
 
Appendix 1 Study design and participant characteristics for eight included studies 
Study ID, 
country, 
publication 
type 
Setting Sample size (n) Age 
 
Sex Disease characteristics  Mean no of 
medications  
RCTs 
Gnjidic 2010, 
Australia, full-
text 15 
Self-care 
retirement 
villages 
115 (intervention 
group n = 57, 
control group n=58) 
Intervention 
group mean ; 
80.4 +/- 5.7 
years, Control 
group 84.1 +/- 
5.7 years  
Intervention group; 
Women = 41 
(71.9%), Men =16 
(28.1%), Control 
group; Women = 15 
(25.9%), Men =43 
(74.1%) 
NR Mean Intervention 
group = 6.7 +/- 3.8 , 
Control group 6.2 +/- 
3.3 
Kersten 2013, 
Norway, full-
text 16 
Nursing 
home 
101 (intervention 
group n=51, control 
group n=50) 87 
were assesses at 
baseline and more 
were lost to follow-
up 
Intervention 
group median 
(IQR); 86 years 
(73-99), 
Control group 
85 years (74-
97) Overall 
mean age 85 
years 
Intervention group; 
Women = 39/47 
(83%), Control 
group; Women = 
30/40 (75%) 
Intervention group; Clinical 
dementia rate 0,1,2 = 
19(40.4%), 17(36.2%), 11 
(23.4%), respectively, Control  
group; Clinical dementia rate 
0,1,2 = 8(20%), 19(47.5%), 13 
(32.5%), respectively 
Median of scheduled 
drugs Intervention 
group = 10 (IQR=7-
13), Control group 
9(IQR=6-11) 
Overall median drugs 
9 
Moga 2017, 
the United 
States, full-
text 17 
Hospital 50 (intervention 
group n = 25, 
control group n=25) 
Intervention 
group mean ; 
76.3 +/- 6.2  
years, Control 
group 79.1 +/- 
6.9 years  
Intervention group; 
Women = 18 
(72.0%), Control 
group; Women = 17 
(68.0%) 
Intervention group; Clinical 
dementia rating 0,0.5,1 = 
20(80.0%), 4(16.0%), 1 (4.0%), 
respectively, Control  group; 
Clinical dementia rate 0,0.5,1 = 
13(52.0%), 8(32.0%), 4(16.0%), 
respectively 
NR 
  
Table
Study ID, 
country, 
publication 
type 
Setting Sample size (n) Age 
 
Sex Disease characteristics  Mean no of 
medications  
van der Meer 
2016, the 
Netherlands, 
conference 
abstract 18 
Community 157,  4.3% drop out mean 75.5 year Women = 70.9% NR 8.9 
Non-randomised PPI studies 
Castelino 
2010, 
Australia, full-
text 19 
Community 372  mean (SD)= 
76.1 (7.8) 
Women = 55.0% mean (SD) chronic medication 
per patient = 6.0 (3.0), 
 mean (SD) regular 
prescription 8.7 (3.0) 
Hanus 2016, 
the United 
States, full-
text 20 
Hospital 59 mean 77 +/- 
9.3 years  
Women = 30 
(50.9%),  
Men =29 (49.1%) 
ER visit = 2.6 +/- 1.8, 
Hospitalisations + ER visit = 1.6 
+/- 1.4, Hospitalisations = 0.7 
+/-1.0 
19.6 +/- 6.7 
Rojo-Sanchıs 
2017, Spain, 
full-text 21 
Hospital 67  mean 91.3 
years 
(95%CI=90.9-
93.6) 
Women = 67.2 % 
(54.6-78.2) 
Dementia 35.8% (95%CI=24.0-
47.6) 
Previous fall 11.9%(95%CI=5.3-
22.2) 
Auditory impairment 
56.7%(95%CI=44.0-68.8), 
Constipation 
25.4%(95%CI=15.5-37.5), 
Stroke 14.9%(95%CI=7.4-25.7),  
DM 16.2%(95%CI=8.3-27.1), 
CKD 36.85(95%CI=25.4-49.3), 
Institutionalised 
32.8%(95%CI=21.8-45.4) 
 
7.6 (95%CI=4.9-10.9) 
Study ID, 
country, 
publication 
type 
Setting Sample size (n) Age 
 
Sex Disease characteristics  Mean no of 
medications  
Tay 2014, the 
United 
Kingdom, full-
text 22 
Hospital 70 each phase  First phase, 
mean (SD);  
84.2 (7.3), 
Second phase 
83.0 
(6.3),p=0.30 
Women; First phase 
76%, Second phase 
61%, p=0.10 
Dementia First phase = 20%, 
Second phase = 19%, p=1; 
Delirium First phase = 37%, 
Second phase = 41%,p=0.73 
First phase = 6, 
Second phase = 7, 
p=0.14 
Note ACB = Anticholinergic Cognitive Burden Scale, ADS= Anticholinergic Drug Scale, ARS = Anticholinergic Risk Scale, CI= Confidential Interval, IQR 
= Interquartile range, no. = Number, NR = Not Reported, SD = Standards Deviation 
 
Appendix 2 Summary of risk of bias assessment of non-randomised PPI studies included in the review, based on SIGN checklist 
 Questions Castelino 
2010 19 
Hanus  
2016 20 
Rojo-
Sanchis 
2017 21 
Tay  
2014 22 
SECTION 1 Internal validity 
1.1 The study addresses an appropriate and clearly focused question. Yes Yes No Yes 
1.2 The two groups being studied are selected from source populations that are comparable 
in all respects other than the factor under investigation. 
NA NA NA NA 
1.3 The study indicates how many of the people asked to take part did so, in each of the 
groups being studied. 
NA NA NA NA 
1.4 The likelihood that some eligible subjects might have the outcome at the time of 
enrolment is assessed and taken into account in the analysis. 
NA NA NA NA 
1.5 What percentage of individuals or clusters recruited into each arm of the study dropped 
out before the study was completed? 
NA NA NA NA 
1.6 Comparison is made between full participants and those lost to follow up, by exposure 
status. 
NA NA NA NA 
1.7 The outcomes are clearly defined. 
Yes No No No 
1.8 The assessment of outcome is made blind to exposure status. If the study is retrospective 
this may not be applicable. 
NA NA Yes NA 
1.9 Where blinding was not possible, there is some recognition that knowledge of exposure 
status could have influenced the assessment of outcome. 
NA NA NA NA 
1.10 The method of assessment of exposure is reliable. 
Yes Yes Yes Yes 
1.11 Evidence from other sources is used to demonstrate that the method of outcome 
assessment is valid and reliable. 
Yes Yes Yes Yes 
 Questions Castelino Hanus  Rojo- Tay  
Table
2010 19 2016 20 Sanchis 
2017 21 
2014 22 
1.12 Exposure level or prognostic factor is assessed more than once. 
Yes Yes Yes Yes 
1.13 The main potential confounders are identified and taken into account in the design and 
analysis. 
Can’t say Can’t say Can’t say Can’t say 
1.14 Have confidence intervals been provided? 
No Yes Yes Yes 
SECTION 2 Overall assessment of the study 
2.1 How well was the study done to minimise the risk of bias or confounding? 
High 
quality 
High 
quality 
High 
quality 
High 
quality 
2.2 Taking into account clinical considerations, your evaluation of the methodology used, and 
the statistical power of the study, do you think there is clear evidence of an association 
between exposure and outcome? 
Yes Yes Yes Yes 
2.3 Are the results of this study directly applicable to the patient group targeted in this 
guideline? 
Yes Yes Yes Yes 
Note NA = Not Applicable 
 
 
 
Appendix 3 Summary of content of interventions (based on TIDieR checklist) reported in the eight included studies 
Study ID Brief name of 
intervention  
Goal of the elements 
essential to the 
intervention 
Material or procedure that is used 
in the intervention 
Intervention 
provider(s) 
Mode of interventional delivery 
RCTs 
Gnjidic 2010 
15 
Information provision 
to GPs on prescribing 
for older people 
The aim of this cluster 
randomized clinical 
trial was to establish 
whether the DBI can 
be used as a clinical 
tool to guide 
prescribing to reduce 
exposure to 
anticholinergic and 
sedative medications 
in community dwelling 
older people. 
The study intervention included a 
letter and phone call to GPs, using 
DBI to prompt them to consider 
dose reduction or cessation of 
anticholinergic and sedative 
medications. For the intervention 
group, a feedback letter was 
designed for GPs. The letter 
included information on the 
evidence base for minimizing DBI, 
a list of their patient's 
medications, information on their 
patient's DBI, and it’ s likely 
impact on the patient's function. 
GPs were asked to consider 
whether the doses of medications 
contributing to the DBI could be 
reduced or withdrawn. 
Geriatrician and 
clinical 
pharmacologist 
The intervention involved using the DBI 
to prompt general practitioners (GPs) to 
consider reducing their patients' 
exposure to medications that have been 
shown to impair function. 
Kersten 
2013 16 
 Pharmacist-initiated 
reduction of ADS 
score after multi-
disciplinary drug 
reviews 
This study investigated 
if reduced 
anticholinergic drug 
burden (facilitated by 
pharmacist 
intervention) could 
improve cognitive 
function in nursing 
home residents 
The intervention was based on a 
multidisciplinary drug review 
within 3 days after the baseline 
assessment. For patients 
randomised to the intervention 
group, the clinical pharmacist 
performed drug reviews guided by 
the ADS score model to advise the 
respective nursing home physician 
Individual 
clinical 
pharmacist 
The clinical pharmacist performed drug 
reviews guided by the ADS score model 
to advice the respective nursing home 
physician whether to discontinue or 
replace an anticholinergic drug with a 
drug alternative with less or no AA. 
Table
Study ID Brief name of 
intervention  
Goal of the elements 
essential to the 
intervention 
Material or procedure that is used 
in the intervention 
Intervention 
provider(s) 
Mode of interventional delivery 
whether to discontinue or replace 
an anticholinergic drug with a 
drug alternative with less or no 
AA. When drug alternatives were 
unavailable, reduction in dosage 
was attempted to reduce the 
anticholinergic burden, but dose 
reductions did not affect the 
patients’ overall ADS score 
Moga 2017 
17 
Targeted patient-
centred pharmacist–
physician team MTM 
intervention  
This study investigated 
whether a targeted 
multidisciplinary team 
intervention would be 
successful at reducing 
inappropriate 
anticholinergic 
medication use in 
older patients enrolled 
in a cohort at the 
Alzheimer’s Disease 
Centre (ADC) at 
University of Kentucky 
(USA) 
All anticholinergic medications 
taken by each participant were 
labelled  “potentially 
inappropriate” and were subject 
to review by the study team .The 
second step was conducted during 
the targeted MTM intervention 
when each of the previously 
flagged medications was 
evaluated using a risk–benefit 
approach with final 
recommendations based on the 
participant’s input and 
preference. 
Pharmacist and 
clinician  
The targeted MTM intervention was 
based on the pharmacist–clinician team 
drug review between enrolment and visit 
1. Typical MTM interventions evaluate all 
medications used by a patient and 
determine treatment necessity and 
potential changes; our intervention only 
targeted medications known to have 
anticholinergic properties. For patients 
randomised to the intervention group, 
the study pharmacist provided a revised 
medication plan based on the drug 
review, which was discussed with the 
participant and/or their Legally 
Authorized Representative. Specifically, 
the proposed plan attempted to 
recommend discontinuation or 
replacement of anypotentially 
inappropriate drug with anticholinergic 
properties, with safer drug alternatives 
(i.e., with less or noanticholinergic 
Study ID Brief name of 
intervention  
Goal of the elements 
essential to the 
intervention 
Material or procedure that is used 
in the intervention 
Intervention 
provider(s) 
Mode of interventional delivery 
activity). When drug alternatives were 
unavailable, reduction in dosage was 
recommended whenever possible to 
reduce the anticholinergic burden. Similar 
to routine clinical practice, the study 
clinician ultimately made the 
recommendations about prescription 
changes to the participant, while the 
study pharmacist was responsible for 
recommendations and provision of 
information to educate the participant 
about medication safety and the 
importance of patient involvement in 
medication awareness and oversight. 
Appropriate changes were determined by 
the licensed prescriber, but the 
participant had the freedom to acceptor 
reject the recommendations 
van der 
Meer 2016 
18 
Medication review by 
a pharmacist  
This study evaluated 
whether medication 
reviews provide an 
effective intervention 
to reduce a patients' 
Drug Burden Index 
(DBI) 
A medication review by the 
pharmacist in cooperation with 
the patient’s general practitioner. 
Pharmacist  NR 
Non-randomised PPI studies 
Castelino 
2010 19 
Home Medicines 
Review (HMR) 
services by 
pharmacists  
The main aim of the 
study was to 
investigate whether 
Home Medicines 
This retrospective study involved 
the collection of a purposive 
sample of de-identified HMR cases 
and reports pertaining to 372 
Pharmacist  The retrospective analysis of medication 
reviews was performed for who received 
and HMR service from the pharmacists 
Study ID Brief name of 
intervention  
Goal of the elements 
essential to the 
intervention 
Material or procedure that is used 
in the intervention 
Intervention 
provider(s) 
Mode of interventional delivery 
Review (HMR) services 
by pharmacists for 
community-dwelling 
older people would 
lead to an 
improvement in the 
use of medications, as 
measured by a 
decrease in the DBI 
score. The study also 
aimed to investigate 
the (i) distribution of 
DBI scores and PIMs 
among older people 
living in the 
community, and (ii) 
impact of pharmacists’ 
recommendations on 
DBI scores and PIMs. 
community dwelling older people 
(aged ≥65 years). Patients were 
referred to the HMR service on 
the basis of standard criteria, e.g. 
taking ≥ 5 regular medications; 
taking >12 doses of 
medication/day ; significant 
changes made to the medication 
regimen in the last 3 months; 
taking a medication with a narrow 
therapeutic index; and recent 
(within the last 4 weeks) discharge 
from a facility/hospital. 
Hanus 2016 
20 
Electronic 
Medication therapy 
recommendation  
This study was to 
determine 
the physician 
acceptance rates of 
medication therapy 
recommendations 
delivered 
electronically by 
means of the ARS 
service. Secondary 
aims included 
A pharmacist-led Electronic Health 
Record-based medication therapy 
recommendation service to notify 
Primary Care Physicians (PCP). 
Patients with an ARS score of 3 or 
more underwent comprehensive 
medical record review to establish 
clinically relevant medication 
therapy recommendations. The 
business intelligence and decision 
support departments at DHS 
Pharmacist-led 
team 
These recommendations were made to 
patients' PCPs via the shared EHR before 
the patient's upcoming visit, with enough 
time for the PCP to evaluate and 
implement them. Finally, post-visit 
recommendation outcomes were 
determined by the pharmacist and 
categorized as “accepted” if implemented 
or “rejected” if ignored. 
Study ID Brief name of 
intervention  
Goal of the elements 
essential to the 
intervention 
Material or procedure that is used 
in the intervention 
Intervention 
provider(s) 
Mode of interventional delivery 
exploring potential 
associations 
between 
recommendation 
acceptance rates and 
patient and 
 provider 
characteristics. 
generated a bimonthly report to 
identify eligible patients for the 
pharmacist-led ARS service. The 
report identified patients at least 
60 years old who had (1) an 
established PCP in the internal 
medicine or family medicine 
department, (2) a PCP visit in the 
following 2-week window, (3) at 
least 3 inpatient hospitalizations 
or emergency department (ED) 
visits in the past year, and (4) at 
least 10 active medications on 
their medication list. ARS score 
was calculated for all eligible 
patients. Patients with an ARS 
score of 3 or more underwent 
comprehensive medical record 
review to establish clinically 
relevant medication therapy 
recommendations. 
Rojo-
Sanchis 
2017 21 
Standard Geriatric 
Pharmaceutical 
practice  
This study was to 
determine, variations 
in anticholinergic 
burden of long-term 
medication in acute 
geriatric patients 
undergoing standard 
geriatric-
pharmaceutical 
During hospitalization, the 
geriatric and pharmaceutical care 
of patients was performed 
according to standard clinical 
practice. Pharmacists collaborated 
in the clinical interview, 
performed medication 
reconciliation, reviewed data from 
the clinical history, validated the 
Individual 
Pharmacist  
Anticholinergic burden was calculated 
according to the score assigned to each 
drug on the ADS, ARS, and ACB scales. 
Thus, the anticholinergic burden of each 
patient on admission and at discharge 
was determined using each of the three 
scales 
Study ID Brief name of 
intervention  
Goal of the elements 
essential to the 
intervention 
Material or procedure that is used 
in the intervention 
Intervention 
provider(s) 
Mode of interventional delivery 
practice between 
admission and 
discharge 
daily treatments based on the 
STOPP/START validation criteria 
and recommended changes on 
patients’ chronic treatments, 
which included deprescription, to 
geriatricians. 
Tay 2014 22 Consultant-led 
medication review 
targeting 
anticholinergics  
The aim of study to 
identify whether a 
consultant-led 
medication review 
targeting 
anticholinergics would 
reduce anticholinergic 
drug exposure 
[number of 
anticholinergic drugs 
and ARS score 
The first phase of audit assessed 
standard practice. Re-audit is a list 
of drugs with ARS scores was then 
pasted on the ward round trolley 
and the doctors’ room wall, as a 
reminder of the anticholinergic 
drugs. 
Multidisciplinary 
team including a 
ward 
pharmacist (1st 
audit only) 
Standard practice involved a review of all 
new admissions to the ward by one of the 
four consultant geriatricians, as well as a 
multidisciplinary team of therapists, 
including a ward pharmacist. They would 
undertake comprehensive geriatric 
assessment, which included a review of 
the appropriateness of prescribed 
medications. Re-audit was undertaken. 
The same four consultants were told 
about the result of the first audit at an 
informal unit presentation. A list of drugs 
with ARS scores was then pasted on the 
ward round trolley and 
the doctors’ room wall, as a reminder of 
the anticholinergic drugs 
Note AA = Anticholinergic Activity, ACB = Anticholinergic Cognitive Burden Scale, ADS= Anticholinergic Drug Scale, ARS = Anticholinergic Risk Scale, 
DBI = Drug Burden Index, HMR = Home Medication Review, MTM = Medication Therapy Management, PIMs = Potential Inappropriate Medications 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 1: PRISMA Flow Diagram 
Excluded due to duplication 
n = 325 
Tiles and abstracts identified and screened 
n = 5543 
Excluded = 5510 
Full-text and conference abstracts 
screened 
n = 33 
(Full text paper = 21) 
(Conference abstract = 12) 
 
Reasons for exclusion: 
Protocol = 2 
Epidemiological study = 2 
Not intervention/strategy to reduce 
anticholinergic burden = 1 
Participants aged lower than 65 were 
included in study = 3    
Measurement of anticholinergic burden 
is not reported or unclear = 9 
Intervention is not to reduce/specify to 
anticholinergic burden = 5 
Anticholinergic is not used in all 
participants = 3 
 
Publications meeting inclusion criteria 
and included in the review 
n = 8 
(Full text = 7) 
(Conference abstract = 1) 
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Figure 2: Risk of bias in individual RCT studies 
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Gnjidic 2010 15 ? ?      
Kersten 2013 16 ?       
Moga 2017 17        
Van der Meer 2016 18 ? ? ? ?    
 Low risk of bias 
 Unclear risk of bias 
 High risk of bias 
Figure
